Allosteric modulation of G protein-coupled receptors

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 5, 2002, Pages 749-755

  Soudijn, Willem ^a   Van Wijngaarden, Ineke ^a   IJzerman, Ad P ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Allosteric modulators; G protein coupled receptors; Positive and negative cooperativity

Indexed keywords

2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 2 AMINOTHIAZOLE DERIVATIVE; 2 CHLORO 6 [3 [1,1 DIMETHYL 2 (2 NAPHTHYL)ETHYLAMINO] 2 HYDROXYPROPOXY]BENZONITRILE; 2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; 4 ANILINO 2 CYCLOPENTYLIMIDAZO[4,5 C]QUINOLINE; 4 METHOXY N [7 METHYL 3 (2 PYRIDINYL) 1 ISOQUINOLINYL]BENZAMIDE; 6 N CYCLOPENTYLADENOSINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; BAY 36 7620; CALCIUM CHANNEL STIMULATING AGENT; CALCIUM ION; CGP 7930; G PROTEIN COUPLED RECEPTOR; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; METHYLPHENYLETHYNYLPYRIDINE; MUSCARINIC RECEPTOR; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; NEW DRUG; RECEPTOR SUBTYPE; T 7; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; ALZHEIMER DISEASE; BINDING SITE; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONVULSION; DRUG EFFECT; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; HEART ARRHYTHMIA; HUMAN; HYPOPARATHYROIDISM; ISCHEMIC HEART DISEASE; LIGAND BINDING; NOCICEPTION; NONHUMAN; OSTEOPOROSIS; PARKINSON DISEASE; RECEPTOR BINDING; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION;

ANIMALS; CALCIUM-BINDING PROTEINS; GTP-BINDING PROTEINS; HUMANS; MOLECULAR CONFORMATION; RECEPTORS, DRUG; RECEPTORS, GABA-B; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, MUSCARINIC; RECEPTORS, PURINERGIC P1;

EID: 0036771048     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Drews J: Drug discovery: A historical perspective. Science (2000) 287:1960-1964.
2. Monod J, Changeux J-P, Jacob F: Allosteric proteins and cellular control systems. J Mol Biol (1963) 6:306-329.
3. Soudijn W, Van Wijngaarden I, IJzerman AP: Allosteric modulation of G-protein-coupled receptors. Expert Opin Ther Patents (2001) 11:1889-1904. This paper should be read as an introduction to the current review.
4. Christopoulos A: Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery. Nat Rev Drug Disc (2002) 1:198-210. This paper gives a detailed account on allosteric modulation of GPCRs, including its 'mathematical' foundation.
5. 1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol (1990) 38:939-949. This is a seminal paper on allosteric modulation of adenosine receptors.
6. 1 adenosine receptor coupling to G proteins. Biochim Biophys Acta Mol Cell Res (1995) 1265:15-21.
7. 1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs. Circ Res (1996) 79:415-423.
8. Bhattacharya S, Linden J: Effects of long-term treatment with the allosteric enhancer, PD81,723, on Chinese hamster ovary cells expressing recombinant human A, adenosine receptors. Mol Pharmacol (1996) 50:104-111.
9. 1 receptor allosteric enhancer PD 81,723 on agonist binding to brain and adipocyte membranes. Brain Res (1999) 840:75-83.
10. 1 receptor. Biochem Pharmacol (2001) 61:137-144.
11. 1 adenosine receptors. J Med Chem (2002) 45:382-389.
12. Van der Klein PA, Kourounakis AP, IJzerman AP: Allosteric modulation of the adenosine A, receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. J Med Chem (1999) 42:3629-3636.
13. Chordia MD, Murphree LJ, Macdonald TL, Linden J, Olsson RA: 2-Aminothiazoles: A new class of agonist allosteric enhancers of A, adenosine receptors. Bioorg Med Chem Lett (2002) 12:1563-1566.
14. 3 adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol Pharmacol (2001) 60:1057-1063.
15. 3 adenosine receptors by a series of imidazoquinoline derivatives. Mol Pharmacol (2002) 62:81-89.
16. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA (1998) 95:4040-4045. This paper is the first disclosure of calcimimetics acting via allosteric mechanisms.
17. Fox J, Lowe SH, Petty BA, Nemeth EF: NPS R-568: A type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther (1999) 290:473-479.
18. Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ: Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent J Clin Endocrinol Metab (1998) 83:1083-1088.
19. Goodman WG, Frazão JM, Tumer SA, Goodkin DA, Liu W, Cobum JW: A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int (2000) 58:436-445.
20. Frazão JM, Martins P, Cobum JW: The calcimimetic agents: Perspectives for treatment Kidney Int (2002) 61:S149-S154.
21. Goodman WG, Hladik GA, Tumer SA, Blaisdell PW, Goodkin DA, Liu W, Bam YM, Cohen RM, Cobum JW: The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol (2002) 13:1017-1024.
22. 2+ receptor antagonists that stimulate secretion of parathyroid hormone. J Pharmacol Exp Ther (2001) 299:323-331.
23. Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, Bhatnagar PK, Lago AM, Callahan JF, DelMar EG, Miller MA et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest (2000) 105:1595-1604.
24. Gasparini F, Kuhn R, Pin JP: Allosteric modulators of group I metabotropic glutamate receptors: Novel subtype-selective ligands and therapeutic perspectives. Curr Opin Pharmacol (2002) 2:43-49.
25. Litschig S, Gaspadni F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, Prézeau L, Pin JP, Thomsen C, Kuhn R: CPCCOET a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol (1999) 55:453-461.
26. Carroll FY, Stolle A, Beart PM, Voerste A, Brabet I, Mauler F, Joly C, Antonicek H, Bockaert J, Müller T, Pin JP, Prézeau L: Bay367620: A potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol Pharmacol (2001) 59:965-973.
27. Gasparini F, Lingenhöhl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendom R, Unwyler S, Varney MA et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology (1999) 38:1493-1503.
28. Pagano A, Ruegg D, Litschig S, Stoehr N, Stierlin C, Heinrich M, Floersheim P, Prézeau L, Carroll F, Pin JP, Cambria A et al. The non-competitive antagonists 2-methyl-6-(phenylethynyl)-pyridine and 7-hydroxyiminocyclopropan[b] chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J Biol Chem (2000) 275:33750-33758.
29. 3H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg Med Chem Lett (2002) 12:407-409.
30. Chapman AG, Nanan K, Meldrum BS, Schreiber R, De Vry J, Müller T: Anticonvulsant activity in mice of BAY 36-7620, a novel, selective mgluR1 antagonist. 30th Annual Meeting of the Society for Neuroscience, New Orleans, LA, USA (2000):Abs 618.10.
31. Chapman AG, Nanan K, Williams M, Meldrum BS: Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6- (phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styrylpyridine (SIB 1893). Neuropharmacology (2000) 39:1567-1574.
32. Spooren WP, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S, Porsolt RD, Gentsch C: Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther (2000) 295:1267-1275.
33. Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R, Pilc A: Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol (2001) 132:1423-1430.
34. Schulz B, Fendt M, Gasparini F, Lingenhöhl K, Kuhn R, Koch M: The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats. Neuropharmacology (2001) 41:1-7.
35. Ossowska K, Konieczny J, Wolfarth S, Wieronska J, Pilc A: Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology (2001) 41:413-420.
36. B receptor. J Biol Chem (2002) 277:3236-3241.
37. B receptors. J Biol Chem (2000) 275:41166-41174.
38. B receptor function. EMBO J (2001) 20:2152-2159. This study relates receptor heterodimedzation to allosteric modulation.
39. B receptors open new routes for the development of drugs targeting family 3 G-protein-coupled receptors. Mol Pharmacol (2001) 60:881-884.
40. Urwyler S, Mosbacher J, Lingenhöhl K, Heid J, Hofstetter K, Froestl W, Bettler B, Kaupmann K: Positive allosteric modulation of native and recombinant y-aminobutyric acid. receptors by 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol (2001) 60:963-971.
41. 4 muscarinic receptors. Life Sci (1999) 64:519-526.
42. MEDCO RESEARCH INC (Baraldi PG): Allosteric adenosine receptor modulators. WO-09921617 (1999).
43. MEDCO RESEARCH INC (Baraldi PG): Thiophenes useful for modulating the adenosine receptor. US-05939432 (1999).
44. MEDCO RESEARCH INC (Baraldi PG): Allosteric adenosine receptor modulators. US-06177444 (2001).
45. MEDCO RESEARCH INC (Baraldi PG): Allosteric adenosine receptor modulators. US-06194449 (2001).
46. NPS PHARMACEUTICALS INC (van Wagenen BC, Moe ST, Balandrin MF, DelMar EG, Nemeth EF): Calcium receptoractive compounds. US-06211244 (2001).
47. NPS PHARMACEUTICALS INC (DelMar EG, Barmore RM, Sheehan D, van Wagenen BC, Callahan JF, Keenan RM, Kotecha NR, Lago MA, Southall LS, Thompson M): Method of using calcilytic compounds. US-06022894 (2000).
48. SANKYO CO LTD (Birdsall N, Lazareno S, Naruto S, Sugimoto M, Koyamo K, Marumoto S): Heterocyclic compounds, their preparation and their therapeutic use. US-05877199 (1999).
49. SANKYO CO LTD (Birdsall N, Lazareno S, Naruto S, Sugimoto M, Koyama K, Marumoto S): Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors. WO-09603377 (1996).
50. SANKYO CO LTD (Hiraoka T, Birdsall N, Gharagozloo P, Lazareno S): Allosteric effectors at muscarinic receptors. GB-02292685 (1996).